Navigation Links
ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Date:8/30/2007

FREMONT, Calif., Aug. 30 /PRNewswire/ -- ARYx Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by ARYx Therapeutics.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated acting as sole book runner and lead manager and CIBC World Markets Corp., Jefferies & Company, Inc. and Leerink Swann & Co., Inc. acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com or by contacting the prospectus department at 180 Varick Street, New York, NY 10014 Attn: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the effic
'/>"/>

SOURCE ARYx Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. PCR Polymerases Application Profiles
3. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
4. Obtaining a contour map from multifiles or 3D data in DataMax
5. Successful stabilization of gene expression profiles
6. Madison biotech NimbleGen files for IPO; one of states best-funded firms
7. Third Wave files countersuit vs. Digene in patent case
8. TomoTherapy files registration statement for IPO
9. Merge files financial reports by market opening
10. The Why Files celebrates decade of science exploration
11. Third Wave files patent suits against Digene, Chiron and Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Global Record Systems, LLC, (GRS), a ... for patients, physicians, the biopharmaceutical industry, regulators, payers, ... signing of a three-year Research Collaboration Agreement (RCA) ... This initiative is designed to generate disruptive ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... N.Y., Aug. 1, 2011 Nycomed US Inc. ("Nycomed US") ... and Chief Executive Officer and member of the Board for ... the closing of the acquisition of Nycomed A/S by Takeda ... Bailey to the newly created position of Chief Operating Officer, ...
... a biopharmaceutical company pioneering a novel class of ... an entirely new class of naturally occurring human ... of these naturally supercharged human proteins enable biologic ... cells. This new class of proteins is the ...
... in the body, then alarm bells start ringing. ... disease and type 2 diabetes, formerly called adult-onset diabetes. ... then they might be able to treat such diseases ... colleagues at the Helmholtz-Zentrum Dresden-Rossendorf and the university in ...
Cached Biology Technology:Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 2Nycomed US Inc. Names Brian A. Markison as Chief Executive Officer 3Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 2Permeon reveals discovery of Intraphilins as new approach to intracellular biologic drugs 3In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3
(Date:7/9/2014)... Tampa, Fla. (July 9, 2014) Emerging fungal ... any other parasitic group, causing population declines of ... from the University of South Florida published in ... amphibians can acquire behavioral or immunological resistance to ... population declines. , "Acquired resistance is important ...
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... new study shows that some shark species may be able ... may come with rising temperatures. , The Arctic today is ... it wasn,t always like that. Roughly 53 to 38 million ... the Arctic was more similar to a huge temperate forest ... including ancestors of tapirs, hippo-like creatures, crocodiles and giant tortoises. ...
Breaking Biology News(10 mins):USF study: Amphibians can acquire resistance to deadly fungus 2Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... replace lost teeth with titanium dental implants could be improved. ... at micro level but also at nano level, researchers at ... method that could shorten the healing time for patients. , ... conductivity of the implant allows us to affect the body,s ...
... new type of cell in the immune system. ... belongs to a family of T-cells that play a critical ... could ultimately lead to the development of novel drugs that ... It is also potentially significant for many other ...
... 2011 Numera, a leading provider of innovative ... entered into a strategic partnership with HealthTrio LLC. ... integrate objective, biometric information from dozens of consumer-preferred ... Health Record (PHR). This new functionality will be ...
Cached Biology News:Healing times for dental implants could be cut 2New cell type offers immunology hope 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 2Numera and HealthTrio LLC Form Partnership to Provide Objective Health Information for Millions of Consumers 3